IRF4 and B-cell chronic lymphocytic leukemia: Furthermore, low IRF4 expression, defined by immunohistochemical stains as less than 20% CD20+ B cells positive for MUM1/IRF4, was reported to be associated with advanced clinical stage, diffuse marrow involvement and reduced time to first treatment (TTFT) in CLL patients.